TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07801495: A Randomized, Double-blind, Placebo-controlled, Multicenter Phase 2a/b Study Assessing the Efficacy, Safety and Tolerability of DDY391 in Participants With Active Moderate to Severe Psoriatic Arthritis

Sponsor: Novartis Pharmaceuticals · Phase: PHASE2 · Area: IMMUNOLOGY · Target Enrollment: 220 pts

Competing Trials Overlap

6 Active Trials

Excess Burn Exposure

$9,556,500

Rescue Site Savings

+$6,313,500

Unlock Full NCT07801495 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07801495 Rescue Dossier →